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Hypertension develops in many patients receiving the
immunosuppressive drug tacrolimus (FK506). One possible
mechanism for hypertension is a reduction in vasodilatory
nitric oxide. We found that tacrolimus and a calcineurin
autoinhibitory peptide significantly decreased vascular
calcineurin activity; however, only tacrolimus altered
intracellular calcium release in mouse aortic endothelial cells.
In mouse aortas, incubation with tacrolimus increased
protein kinase C activity and basal endothelial nitric oxide
synthase phosphorylation at threonine 495 but reduced
basal and agonist-induced endothelial nitric oxide synthase
phosphorylation at serine 1177, a mechanism known to
inhibit synthase activity. While this decreased nitric oxide
production and endothelial function, the calcineurin
autoinhibitory peptide had no such effects. Inhibition of
ryanodine receptor opening or protein kinase C blocked the
effects of tacrolimus. Since it is known that the FK506 binding
protein (FKBP12/12.6) interacts with the ryanodine receptor
to regulate calcium release, we propose this as the
mechanism by which tacrolimus alters intracellular calcium
and endothelial nitric oxide synthase rather than by its effect
on calcineurin. Our study shows that prevention of the
tacrolimus-induced intracellular calcium leak may attenuate
endothelial dysfunction and the consequent hypertension.
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The immunosuppressive drug tacrolimus (FK506) is used
clinically to reduce rejection in renal transplant recipients;
however, hypertension develops in many of these patients.1
Post-transplant hypertension is a significant risk factor for
allograft vasculopathy (an accelerated form of atherosclero-
sis), peripheral artery disease, and decreased allograft and
patient survival.2–4 The mechanisms by which tacrolimus
elicits hypertension are not completely understood but are
believed to originate in the vasculature.5 A likely pathogenetic
candidate is endothelial dysfunction and more specifically a
decrease in production of the vasodilator nitric oxide (NO)
by endothelial NO synthase (eNOS). A limited number of
animal studies have examined the role of endothelial
dysfunction and NO bioavailability in tacrolimus-induced
hypertension. Treatment of rats with tacrolimus for 2–3
weeks increases systolic blood pressure and decreases
mesenteric endothelium-dependent relaxation responses, as
well as aortic eNOS activity.6,7 Additionally, acute treatment
of human and rat resistance vessels with pharmacological
concentrations of tacrolimus decreases endothelium-depen-
dent dilation.6 We reported previously that acute treatment
of mouse aortas with tacrolimus attenuates peak NO
production, NO release, and endothelium-dependent
relaxation responses in a concentration-dependent manner.8
These findings suggest that tacrolimus directly impairs
vascular NO biosynthesis; however, the mechanisms remain
unknown.
The decrease in aortic eNOS activity and vasodilator
function by tacrolimus may be due to several factors. The
formation of NO from eNOS is dependent on Ca2þ /
calmodulin and is regulated by numerous factors, including
changes in phosphorylation status.9 Tacrolimus binds its
intracellular target FK506-binding proteins 12 and 12.6
(FKBP12/12.6) and this complex then binds to and inhibits
the Ca2þ /calmodulin-dependent phosphatase calcineurin
(protein phosphatase 2B). The inhibition of calcineurin in
lymphocytes prevents NF-AT-mediated proliferation leading
to immune suppression. However, the binding of FKBP12/
12.6 and inhibition of calcineurin also occur in non-immune
cells such as endothelial cells and elicit numerous effects,
many of which are unknown. One known effect is the
displacement of FKBP12/12.6 by tacrolimus from intracel-
lular Ca2þ release channels (ryanodine receptors, RyRs)
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leading to an intracellular Ca2þ leak mediated by increased
probability and duration of RyR opening.8,10–12 We reported
previously that tacrolimus-mediated removal of FKBP12/12.6
from RyRs in mouse aortic endothelial cells (MAECs) causes
a concentration-dependent Ca2þ leak and decreases agonist-
induced intracellular Ca2þ release.8 However, it remains
unknown whether this alteration in intracellular Ca2þ
handling alters eNOS phosphorylation and contributes to
the decrease in eNOS activity by tacrolimus.
Earlier studies suggested that tacrolimus-induced hyper-
tension was caused by the inhibition of calcineurin in the
peripheral vasculature as another immunosuppressive drug
that inhibits calcineurin, ciclosporin, also causes hyperten-
sion.13,14 Calcineurin has been reported to decrease
phosphorylation of eNOS at the inhibitory site threonine
495 (Thr495) in response to bradykinin; however, other
studies reported PP1 and PP2A as the phosphatases that
dephosphorylate Thr495.15–17 Another possibility is that the
binding of these drugs to their immunophilins (FKBP12/12.6
for tacrolimus and cyclophilin A for ciclosporin) may
mediate the detrimental vascular and blood pressure effects.
Sirolimus, an immunosuppressive drug structurally similar to
tacrolimus that binds FKBP12/12.6 but has no effect on
calcineurin, is also associated with endothelial dysfunction
and hypertension. We reported previously that vascular
depletion of FKBP12/12.6 by genetic deletion of FKBP12.6 or
sirolimus increases conventional protein kinase C (cPKC)-
mediated eNOS phosphorylation at Thr495 and decreases
NO production and endothelium-dependent dilation.12
Whether tacrolimus decreases eNOS activity by inhibiting
calcineurin-mediated dephosphorylation or by increasing
cPKC-mediated phosphorylation of eNOS Thr495 has not
been examined.
On the basis of our previous data and others, we
hypothesized that tacrolimus decreases vascular eNOS
activity by reducing agonist-induced intracellular Ca2þ levels
and by preventing stimulatory changes in eNOS phosphor-
ylation, but not through its effects on calcineurin. To test this,
we measured intracellular Ca2þ levels in primary MAECs
treated acutely with tacrolimus or a specific calcineurin
inhibitor, calcineurin autoinhibitory peptide (CAIP). We also
measured aortic PKC activity, eNOS Thr495 and Ser1177
phosphorylation, NO production, and endothelium-depen-
dent dilation in mouse aortas treated acutely with tacrolimus
or CAIP to examine the direct vascular effects.
RESULTS
Effect of tacrolimus and CAIP on intracellular calcineurin
activity and Ca2+ levels
To verify the calcineurin-inhibiting effects of both tacrolimus
and CAIP, we measured aortic calcineurin activity following
in vitro treatment with either tacrolimus (1 mmol/l) or CAIP
(10 mmol/l) for 20 min. Figure 1 demonstrates that both
tacrolimus and CAIP at the concentrations and durations
used throughout the study significantly inhibited aortic
calcineurin activity by 77 and 87%, respectively.
To determine the effects of tacrolimus and CAIP on
endothelial intracellular Ca2þ homeostasis, we performed
ratiometric Ca2þ imaging in primary MAECs. Tacrolimus
(1 mmol/l) induced an intracellular Ca2þ leak of B20% of
the maximal acetylcholine (Ach)-induced intracellular Ca2þ
release in non-treated control MAECs (Figure 2a). Inhibition
of RyR opening with ryanodine abolished the intracellular
Ca2þ leak following tacrolimus, which supports previous
findings that FKBP12/12.6 removal from RyRs mediates the
intracellular Ca2þ leak. In contrast, CAIP (10 mmol/l) had no
effect on basal intracellular Ca2þ levels. In response to ACh,
peak Ca2þ release was markedly decreased in tacrolimus-
treated MAECs (50±5%; Po0.05 versus controls) followed
by a sustained release of 30–35% (Figure 2b). These responses
were normalized by ryanodine. CAIP had no effect on ACh-
induced intracellular Ca2þ release (Figure 2b).
Effect of tacrolimus and CAIP on eNOS phosphorylation
To determine whether inhibition of FKBP12/12.6 or calci-
neurin may contribute to altered eNOS phosphorylation, we
measured aortic eNOS phosphorylation at an inhibitory site,
Thr495, and at a stimulatory site, Ser1177, following in vitro
treatment with either tacrolimus or CAIP. Tacrolimus
significantly increased basal phosphorylation of eNOS at
Thr495 (Figure 3) and decreased basal phosphorylation of
eNOS at the stimulatory site Ser1177 (Figure 4) compared
with controls; however, CAIP had no effect on either
phosphorylation site. Agonist-induced increases in eNOS
Ser1177 phosphorylation were evident in non-treated control
aortas (Figure 4). However, these changes were attenuated by
tacrolimus but not by CAIP (Figure 4). As PKC is known to
phosphorylate eNOS at Thr495 and decrease eNOS Ser1177
phosphorylation and activity, we tested whether inhibition of
the Ca2þ -dependent PKC isoforms (cPKC) could prevent the
tacrolimus-induced changes in eNOS phosphorylation.
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Figure 1 | Effect of tacrolimus and calcineurin autoinhibitory
peptide on vascular calcineurin activity. Both tacrolimus (TAC;
1 mmol/l) and calcineurin autoinhibitory peptide (CAIP; 10mmol/l)
significantly decreased aortic calcineurin activity. Human recombinant
calcineurin was used as a positive control (Pos Con). Results are
expressed as mean±s.e.m. (n¼ 2–3 pooled aortas for each group and
three independent experiments). *Po0.05 versus control.
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Co-incubation of aortas with the cPKC inhibitor Go¨6976
prevented the increase in eNOS Thr495 phosphorylation and
the basal and agonist-induced decrease in eNOS Ser1177
phosphorylation by tacrolimus (Figures 3 and 4). Addition-
ally, inhibition of the intracellular Ca2þ leak with ryanodine
prevented the increase in eNOS Thr495 phosphorylation
induced by tacrolimus (Figure 3). These findings support our
hypothesis that altered endothelial intracellular Ca2þ levels
through tacrolimus–FKBP12–RyR interaction negatively
affects eNOS phosphorylation, but acute, direct inhibition
of calcineurin does not affect basal or agonist-induced eNOS
phosphorylation.
Effect of tacrolimus and CAIP on vascular PKC activity
As cPKC inhibition prevented the detrimental effects of
tacrolimus on eNOS phosphorylation, we tested whether
tacrolimus increased PKC activity and whether this was due
to the intracellular Ca2þ leak by measuring PKC Ser660
phosphorylation.18 Tacrolimus significantly increased PKC
Ser660 phosphorylation compared with controls (Figure 5);
however, CAIP had no effect. The tacrolimus-induced
increase in PKC Ser660 phosphorylation was not blocked
by Go¨6976; however, this was expected as Go¨6976 inhibits the
ATP-binding site on cPKC and its catalytic activity but has no
Phospho-eNOS Thr495
eNOS
200
150
100
50
0
%
 C
ha
ng
e 
in
 p
ho
sp
ho
-e
NO
S
Th
r4
95
/e
N
O
S 
ra
tio
*
Co
ntr
ol
TA
C
TA
C+
Gö
69
76 TA
C+
Ry
anCA
IP
Figure 3 | Effect of tacrolimus and calcineurin autoinhibitory
peptide on endothelial nitric oxide synthase (eNOS) Thr495
phosphorylation. Tacrolimus (TAC; 1 mmol/l) increased eNOS
Thr495 phosphorylation, which was reversed by the conventional
protein kinase C (cPKC) inhibitor Go¨6976 (1 mmol/l) or the RyR
inhibitor ryanodine (Ryan; 50 mmol/l). Calcineurin autoinhibitory
peptide (CAIP; 10 mmol/l) had no effect on eNOS Thr495
phosphorylation. (a) Representative western blots showing aortic
eNOS Thr495 phosphorylation and eNOS expression. (b)
Densitometry for ratio of eNOS Thr495 phosphorylation to eNOS
expression as a percentage of control. Results are expressed as
mean±s.e.m. (n¼ 3 pooled aortas for each group and three
independent experiments). *Po0.05 versus control.
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Figure 4 | Effect of tacrolimus and calcineurin autoinhibitory
peptide on endothelial nitric oxide synthase (eNOS) Ser1177
phosphorylation. Tacrolimus (TAC; 1 mmol/l) decreased both
basal and acetylcholine-induced eNOS Ser1177 phosphorylation,
which was reversed by the conventional protein kinase C (cPKC)
inhibitor Go¨6976 (1 mmol/l). Calcineurin autoinhibitory peptide
(CAIP; 10 mmol/l) had no effect on eNOS Ser1177 phosphorylation.
(a) Representative western blots showing basal and acetylcholine-
induced aortic eNOS Ser1177 phosphorylation and eNOS
expression. (b) Densitometry for ratio of eNOS Ser1177
phosphorylation to eNOS expression as a percentage of control.
Results are expressed as mean±s.e.m. (n¼ 3 pooled aortas for each
group and three independent experiments). *Po0.05 versus control.
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Figure 2 | Effect of tacrolimus and calcineurin autoinhibitory
peptide on endothelial intracellular Ca2+ levels. Experiments
were performed in aortic endothelial cells from control mice in the
absence of extracellular Ca2þ (a) Tacrolimus (TAC; 1 mmol/l)
caused an intracellular Ca2þ leak, which was prevented by
ryanodine (Ryan; 50 mmol/l). Calcineurin autoinhibitory peptide
(CAIP; 10mmol/l) had no effect endothelial intracellular Ca2þ
levels. (b) Tacrolimus-treated control aortic endothelial cells
exhibited decreased acetylcholine-induced (ACh; 1 mmol/l)
intracellular Ca2þ release, which was augmented by Ryan
(50mmol/l). CAIP (10 mmol/l) had no effect. Results are expressed
as the mean change in 340/380 nm ratio as a percentage of the
peak response to ACh in untreated controls (n410 cells from
three to five mice for each group).
Kidney International (2009) 75, 719–726 721
LG Cook et al.: Tacrolimus and endothelial nitric oxide synthase o r i g i n a l a r t i c l e
effect on PKC autophosphorylation and activation.19
However, the increase in PKC Ser660 phosphorylation by
tacrolimus was blocked by ryanodine, suggesting that a RyR-
mediated Ca2þ leak contributes to PKC activation and eNOS
Thr495 phosphorylation.
Effect of tacrolimus and CAIP on aortic NO production
To verify that tacrolimus decreases vascular eNOS activity as
previously reported,7 we measured NO production in aortic
homogenates using 4-amino-5-methylamino-20,70-difluoro-
fluorescein (DAF-FM) diacetate. Tacrolimus decreased peak
aortic NO production by 88% compared with untreated
controls (No-nitro-L-arginine (L-NNA)-sensitive peak DAF-
FM fluorescent counts: tacrolimus¼ 36,456±7548 and
controls¼ 303,128±19,457, Po0.05 versus controls;
Figure 6). However, acute treatment with CAIP did not
affect peak aortic NO production when compared with
controls (Figure 6). Inhibition of cPKC activity with Go¨6976
increased peak NO production significantly in tacrolimus-
treated aortas and untreated control aortas (L-NNA-sensitive
peak DAF-FM fluorescent counts: tacrolimusþGo¨6976¼
414,697±20,730 and controlþGo¨6976¼ 422,284±22,602,
P40.05 versus non-treated controls; Figure 6). Additionally,
blockade of the tacrolimus-induced Ca2þ leak with ryano-
dine restored peak NO production to control levels and had
no significant effect in untreated aortas (Figure 6).
Effect of tacrolimus and CAIP on endothelium-dependent
and -independent relaxation
To test whether acute inhibition of FKBP12/12.6 or
calcineurin had functional vascular effects, we measured
aortic endothelium-dependent and -independent relaxation
responses in isolated mouse aortas treated with tacrolimus or
CAIP. Tacrolimus significantly decreased maximal ACh-
induced relaxation responses compared with non-treated
controls (relaxation from phenylephrine-induced contrac-
tion: tacrolimus¼ 31±3% and controls¼ 80±4%; Po0.05
versus controls; Figure 7a). In both groups, the NOS
inhibitor L-NNA (10 mmol/l) abolished relaxation responses
to ACh (Figure 7a). However, CAIP, at concentrations
ranging from 0.1 to 10 mmol/l, had no effect on endothe-
lium-dependent relaxation responses (Figure 7b). Inhibition
of cPKC isoforms specifically with Go¨6976 (1mmol/l)
increased the sensitivity to ACh significantly in tacrolimus-
treated and control aortas (Figure 7c). Ryanodine (50 mmol/l)
also restored relaxation responses in tacrolimus-treated
aortas to control levels, but had no significant effect on
relaxation responses in untreated aortas (Figure 7d). The
restoration of relaxation responses by Go¨6976 or ryanodine
was blocked by L-NNA (data not shown), supporting the
findings in Figure 6 that inhibition of RyR opening or cPKC
activity increased NO production in tacrolimus-treated
aortas. Neither tacrolimus nor CAIP had an effect on
maximal endothelium-independent relaxation responses or
sensitivity to the NO donor sodium nitroprusside compared
with controls (data not shown).
DISCUSSION
The mechanisms by which tacrolimus decreases eNOS
activity and causes endothelial dysfunction and hypertension
are largely unknown. The aim of this paper was to address
three questions: (1) does tacrolimus decrease vascular
eNOS activity and NO production by altering eNOS
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Figure 6 | Effect of tacrolimus and calcineurin autoinhibitory
peptide on peak aortic NO production. Tacrolimus (TAC;
1 mmol/l) decreased N o-nitro-L-arginine (L-NNA)-sensitive 4-amino-
5-methylamino-20,70-difluorofluorescein (DAF-FM) fluorescence,
which was increased significantly by the conventional protein
kinase C (cPKC) inhibitor Go¨6976 (1 mmol/l) or normalized by the
RyR inhibitor ryanodine (Ryan; 50 mmol/l). Calcineurin
autoinhibitory peptide (CAIP; 10 mmol/l) had no effect on aortic
L-NNA-sensitive DAF-FM fluorescence. Results are expressed as
mean±s.e.m. (n¼ 5 mice for each group). *Po0.05 versus
control.
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Figure 5 | Effect of tacrolimus and calcineurin autoinhibitory
peptide on protein kinase C (PKC) Ser660 phosphorylation.
Tacrolimus (TAC; 1 mmol/l) increased PKC Ser660 phosphorylation,
which was reversed by the RyR inhibitor ryanodine (Ryan;
50mmol/l). The cPKC inhibitor Go¨6976 (1 mmol/l) or calcineurin
autoinhibitory peptide (CAIP; 10mmol/l) had no effect. (a)
Representative western blots showing aortic PKC Ser660
phosphorylation. (b) Densitometry for ratio of PKC Ser660
phosphorylation to b-Actin as a percentage of control. Results are
expressed as mean±s.e.m. (n¼ 3 pooled aortas for each group
and three independent experiments). *Po0.05 versus control.
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phosphorylation, (2) is the altered eNOS phosphorylation
due to changes in intracellular Ca2þ levels, and (3) does
calcineurin inhibition by tacrolimus play a role. Our findings
demonstrate that a pharmacological concentration of tacro-
limus causes an endothelial intracellular Ca2þ leak and
decreases agonist-induced intracellular Ca2þ release that
negatively affects eNOS phosphorylation, NO production,
and endothelium-dependent dilation. This decrease in
vasodilator function by tacrolimus may be due to an increase
in cPKC-mediated phosphorylation of eNOS at Thr495 and
result from the displacement of FKBP12/12.6 from endothe-
lial RyRs and altered intracellular Ca2þ release. Our data do
not support a role for acute calcineurin inhibition in the
decreased eNOS activity caused by tacrolimus.
We previously reported that tacrolimus and sirolimus
exert detrimental effects on NO production and vasodilation
through FKBP12/12.6 displacement from endothelial RyRs
and the resulting intracellular Ca2þ leak.8 Furthermore, we
have demonstrated that the endothelial intracellular Ca2þ
leak induced by sirolimus leads to increased cPKC-mediated
eNOS Thr495 phosphorylation, which blocks calmodulin
binding to eNOS and stimulation of eNOS activity.12
However, it remained unknown whether tacrolimus alters
eNOS phosphorylation and the mechanisms involved (i.e.,
FKBP12/12.6 versus calcineurin). In the current study,
tacrolimus, such as sirolimus, increased phosphorylation of
eNOS Thr495, and decreased eNOS Ser1177 phosphoryla-
tion, peak NO production, and endothelium-dependent
relaxation responses in mouse aortas. Additionally, agonist-
induced intracellular Ca2þ release was markedly attenuated
in MAECs treated with tacrolimus confirming our previous
study.8 The basal Ca2þ leak and reduced agonist-induced
Ca2þ release likely prevents the achievement of the
intracellular Ca2þ threshold needed for eNOS activation.
The basal RyR-mediated Ca2þ leak increases cPKC-mediated
eNOS Thr495 phosphorylation and the reduced agonist-
induced intracellular Ca2þ levels prevent eNOS Thr495
dephosphorylation, which is necessary for calmodulin
binding, eNOS Ser1177 phosphorylation, and eNOS activity.
Evidence to support this comes from the findings that
restoration of agonist-induced intracellular Ca2þ release
through ryanodine in tacrolimus-treated endothelial cells was
associated with decreased aortic eNOS Thr495 and PKC
activation and increased aortic eNOS Ser1177 phosphoryla-
tion, NO production, and endothelium-dependent dilation.
Although ryanodine can open RyRs at low concentrations,
micromolar concentrations, such as that used here, lock the
channel in a closed state supporting our hypothesis that a
tacrolimus-induced, RyR-mediated Ca2þ leak initiates this
pathway. These data confirm and extend our previous
findings that displacement of FKBP12/12.6, either pharma-
cologically or genetically, from endothelial RyRs alters
intracellular Ca2þ , which affects numerous endothelial cell
signaling pathways that modulate vascular tone including
eNOS and cPKC activation. Furthermore, the current
findings support the importance of eNOS Thr495 (de)phos-
phorylation in endothelial function and adds tacrolimus to
the growing list of molecules that increase eNOS Thr495
phosphorylation and cause endothelial dysfunction, includ-
ing sirolimus, b-amyloid peptide, and homocysteine.12,18,20
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Figure 7 | Effect of tacrolimus and calcineurin autoinhibitory peptide on endothelium-dependent aortic relaxation responses. (a)
Tacrolimus (TAC; 1 mmol/l) decreased acetylcholine-induced relaxation responses and No-nitro-L-arginine (L-NNA) abolished all relaxation
responses. (b) Calcineurin autoinhibitory peptide (CAIP; 0.1–10 mmol/l) had no effect on acetylcholine-induced aortic relaxation responses.
Acetylcholine-induced relaxation responses were (c) increased significantly by the cPKC inhibitor Go¨6976 (1 mmol/l) or (d) normalized by the
RyR inhibitor ryanodine (Ryan; 50 mmol/l). Results are expressed as mean±s.e.m. (n¼ 4–7 mice for each group). *Po0.05 versus control.
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As both calcineurin inhibitors, ciclosporin and tacrolimus,
cause endothelial dysfunction and hypertension, earlier
studies attributed these side effects to the inhibition of the
Ca2þ /calmodulin-dependent phosphatase.13,14 However, the
lack of studies using a direct, specific calcineurin inhibitor
has made it difficult to interpret previous results. Our data
demonstrate that acute treatment with the calcineurin
inhibitor CAIP, at a concentration that inhibits 87% of
calcineurin activity and is similar to that achieved in patients
treated with tacrolimus,21 had no direct effect on eNOS
phosphorylation, NO production, and endothelium-depen-
dent relaxation responses in control mouse aortas, suggesting
that the immunophilins cyclophilin A and FKBP12/12.6
mediate the detrimental effects of ciclosporin and tacrolimus,
respectively, on endothelial function. Cyclophilin A has been
shown to mediate several cellular processes, including
cholesterol trafficking to caveolae, proinflammatory
responses, cell proliferation and apoptosis, and protein
folding and isomerization.22–25 With respect to endothelial
function, ciclosporin analogs that bind cyclophilin A, but do
not inhibit calcineurin, were reported to have a dose-
dependent cytotoxic/proapoptotic effect on cultured en-
dothelial cells; an effect not duplicated by CAIP.22 Addition-
ally, cyclophilin A interacts with caveolin-1 in caveolae, and
ciclosporin disrupts this complex, the cholesterol content of
caveolae, and the plasmalemmal localization of eNOS.26
Further supportive evidence for immunophilin involvement
in vascular function comes from the findings that calcineur-
in-knockout mice do not exhibit systolic blood pressures
different from control mice either at rest or when challenged
with angiotensin II, whereas FKBP12.6 knockout mice
exhibit hypertension.27,28 Furthermore, sirolimus, which
binds FKBP12/12.6 but inhibits mTOR, also leads to altered
eNOS phosphorylation, endothelial dysfunction, and hyper-
tension in animals and the reported incidence of hypertension
in sirolimus-treated patients is increasing. Taken together, the
immunophilins that bind tacrolimus, sirolimus, and ciclosporin
may be the primary mediators affecting vasodilator function
and blood pressure regulation; however, more studies are
needed to determine the role of cyclophilin A in ciclosporin-
induced hypertension to confirm this hypothesis.
We cannot rule out the long-term effects of calcineurin
inhibition on NO production and endothelial function. One
of the downstream targets of calcineurin is the transcription
factor NF-AT, which translocates to the nucleus upon
dephosphorylation by calcineurin. Ritter et al.29 elegantly
showed that two consensus NF-AT-binding sites exist on the
eNOS promoter (with one being a typical NF-AT/AP-1-
binding site) and direct calcineurin inhibition decreased
angiotensin II AT2-receptor-induced eNOS promoter activity
and eNOS expression in myocardium. However, studies
performed in bovine aortic endothelial cells reported that
ciclosporin and tacrolimus at doses similar to that used in
this study increases eNOS transcription through AP-1.30,31
Thus, it is unknown whether chronic, direct calcineurin
inhibition alters vascular eNOS expression. Another
phosphorylation site on eNOS, Ser116, decreases agonist-
induced NO production and may also contribute to the
tacrolimus-induced decrease in eNOS activity and endothe-
lial dysfunction. Kou et al.32 reported that in response to the
eNOS agonist vascular endothelial growth factor, eNOS
Ser116 may be dephosphorylated by calcineurin and
phosphorylated by PKC as these were blocked by ciclosporin
and the PKC inhibitor calphostin, respectively. On the basis
of the current findings, it is plausible that the binding of
ciclosporin to its immunophilin leads to increased PKC-
mediated eNOS Ser116 phosphorylation and this may
explain their results. Studies are underway to determine the
role of eNOS Ser116 phosphorylation in tacrolimus- and
sirolimus-induced endothelial dysfunction and which PKC
isoforms are responsible for phosphorylating the eNOS-
inhibitory sites.
In conclusion, these data demonstrate that tacrolimus
abrogates NO production and endothelial vasodilator func-
tion by negatively altering endothelial intracellular Ca2þ and
eNOS phosphorylation. These acute, direct effects are
mediated by FKBP12/12.6 and not through the inhibition
of calcineurin. The development and implementation of
tacrolimus derivatives that inhibit calcineurin directly in
lymphocytes but do not bind FKBP12/12.6 or alter eNOS
phosphorylation in endothelial cells may markedly reduce the
incidence of tacrolimus-induced hypertension.
MATERIALS AND METHODS
Animals
Male C57Bl/6 mice (Harlan, Indianapolis, IN, USA) aged 10–18
weeks were used in all experiments. Mice were maintained on a
12:12 light–dark cycle and had access to standard chow ad libitum.
All procedures were approved by the respective Institutional Animal
Care and Use Committees.
Calcineurin activity assay
Endothelium-intact aortas from control mice were isolated, cleaned
in fresh physiological salt solution (119.0 mmol/l NaCl, 4.7 mmol/l
KCl, 1.18 mmol/l KH2PO4, 1.17 mmol/l MgSO4  7H2O, 25 mmol/l
NaHCO3, 11.1 mmol/l dextrose, and 2.5 mmol/l CaCl2), and then
treated with tacrolimus (1 mmol/l, 20 min), CAIP (10 mmol/l,
20 min), or vehicle (dimethyl sulfoxide (DMSO) o0.01% for
tacrolimus). Two to three aortas from each group were pooled
together and then homogenized in the presence of fresh protease
inhibitors. Calcineurin activity was measured using the Colorimetric
Calcineurin Cellular Activity assay from Calbiochem (San Diego,
CA, USA) as per the manufacturer’s protocol. In brief, depho-
sphorylation of the RII peptide in the absence and presence of EGTA
was measured using malachite green, and the amount of phosphate
released was read at 620 nm using a spectrophotometer. Recombi-
nant human calcineurin was used as a positive control and the
results are presented as a percentage of control for each independent
experiment.
Intracellular Ca2+ imaging in MAECs
Primary MAECs were isolated using Matrigel (BD Biosciences
Discovery Labware, Franklin Lakes, NJ, USA) and intracellular Ca2þ
levels were measured as described previously.12 MAECs were loaded
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with Fura-2 AM (10 mmol/l) diluted in physiological salt solution
and were imaged on a Nikon Eclipse E600FN equipped with a
Cascade 512B CCD camera (Photometrics, Tucson, AZ, USA). Cells
were placed in zero Ca2þ physiological salt solution (no CaCl2,
100mmol/l EGTA) and alternately excited at 340 and 380 nm. After a
5 min baseline, cells were treated with either tacrolimus (1 mmol/l),
CAIP (10mmol/l), or vehicle (DMSO o0.01% for tacrolimus) for
15 min. To increase Ca2þ mobilization from intracellular stores,
cells were treated with ACh (1 mmol/l) and monitored for 5 min.
Sixteen-bit time-lapsed fluorescent images (B30 Hz) were collected
at an emission wavelength of 510 nm throughout. In parallel
experiments, endothelial cells were pretreated with ryanodine
(50mmol/l, 60 min) to inhibit RyR opening.
Immunoblotting
Endothelium-intact aortas were treated with tacrolimus (1 mmol/l,
20 min), with or without the cPKC-specific inhibitor Go¨6976
(1mmol/l, 20 min) or ryanodine (50 mmol/l, 60 min), CAIP
(10mmol/l, 20 min), or vehicle (DMSO o0.01% for tacrolimus)
and then homogenized in the presence of fresh protease inhibitors.
The homogenate was centrifuged at 11,000 r.p.m. for 10 min at 41C.
Protein concentration was determined by Lowry assay using bovine
serum albumin as the standard.33 Vascular homogenates (30 mg for
phospho-PKC Ser660 and 60 mg for phospho-eNOS) were separated
by electrophoresis on 4–12% gradient SDS polyacrylamide gels and
then transferred to Immobilon-FL PVDF membranes (Millipore,
Billerica, MA, USA) as described previously.12 Western blot analyses
were performed using the following primary antibodies: eNOS
1:2500 (BD Biosciences Transduction Labs, Franklin Lakes, NJ,
USA), phospho-eNOS Thr495 1:1000 (Cell Signaling, Danvers, MA,
USA), phospho-eNOS Ser1177 1:1000 (Cell Signaling), phospho-
PKC Ser660 1:1000 (Cell Signaling), and b-actin 1:5000 (Sigma, St
Louis, MO, USA). Secondary antibodies consisted of anti-mouse
and anti-rabbit IgGs conjugated to Alexa-Fluor 680 and IR800Dye
(LI-COR Biosciences, Lincoln, NE, USA), respectively. The bands
for phospho-eNOS Thr495/eNOS, phospho-eNOS Ser1177/eNOS,
and phospho-PKC Ser660/b-actin were identified simultaneously
(800 and 700 nm wavelengths, respectively) using infrared visualiza-
tion (Odyssey System; LI-COR Biosciences) and densitometry was
performed using the Odyssey software.
NO production
NO production was measured using the cell-permeable dye DAF-FM
diacetate (Invitrogen Molecular Probes, Carlsbad, CA, USA) as
described previously.12 In brief, 20 mg of protein, 12 mmol/l DAF-FM
diacetate, and water were added to the assay buffer to a final volume
of 1 ml and the sample was stirred continuously and warmed to
371C. Fluorescence was recorded for 20 min using a spectro-
fluorometer with an excitation wavelength of 510 nm, an emission
wavelength of 530 nm, a bandwidth of 4 nm, and a count rate of 1
per second. Fluorescence was also measured following NOS
inhibition with L-NNA (100 mmol/l, 20 min). NO production was
determined by measuring peak fluorescent counts in the absence of
L-NNA minus peak fluorescent counts in the presence of L-NNA.
Organ chamber experiments
Vascular reactivity was measured as described previously.12 Mice
were anesthetized with isoflurane and killed by cervical dislocation.
Indomethacin (10 mmol/l, 45 min) was present for all experiments to
inhibit cyclooxygenase. Endothelium-intact aortic rings were
incubated with or without tacrolimus (1 mmol/l, 20 min), L-NNA
(10mmol/l, 20 min), ryanodine (50 mmol/l, 60 min), Go¨6976
(1mmol/l, 20 min), CAIP (0.1–10 mmol/l, 20 min), or vehicle (DMSO
o0.01% for tacrolimus). Concentration–force curves were obtained
in a half-log, cumulative manner to the endothelium-dependent
dilator ACh and the endothelium-independent dilator sodium
nitroprusside following contraction to an EC70 concentration of
phenylephrine.
Statistical analyses
Results are presented as mean±s.e.m. The two-tailed Student’s t-test
was used to compare the variables between two groups. An analysis
of variance was used for multiple comparisons followed by the
Student’s–Newman–Keuls post hoc test when necessary. The
significance level was 0.05.
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